Basecamp Research Raises £45.9M To Accelerate Life Science AI Breakthroughs
Basecamp Research, a pioneering AI organization focusing on addressing the most significant challenges in the life sciences sector, has announced a groundbreaking multi-year collaboration with Dr. David R. Liu’s laboratory at the Broad Institute of MIT and Harvard. In addition to this collaboration, Basecamp Research has successfully completed a Series B financing round, raising $60 million (£45.9 million) led by Singular. Notably, Dr. Liu holds the positions of Howard Hughes Medical Institute Investigator and Core Member at the Broad, which adds considerable credibility to this partnership. This collaboration signals a significant step forward in advancing methodologies related to programmable genetic medicines, promising transformative treatments for a wide array of diseases.
The partnership between Basecamp Research and Dr.
Liu’s lab promises to usher in novel approaches in the realm of programmable genetic therapeutics. According to Dr. Glen Gowers, co-founder and CEO of Basecamp Research, the goal is to extend the limits of AI in biological design. "We are focusing on closing the essential data gap faced by the biotech industry," Gowers stated, "as our advanced technology continues to generate insightful revelations, venturing beyond the boundaries of known biology every day." This collaboration will combine Dr. Liu's exceptional expertise in genome editing and wet-lab development with Basecamp's extensive proprietary datasets and innovative AI models, fostering a synergy that could yield revolutionary advancements in genetic medicine.
The recent Series B financing round marks a significant milestone for Basecamp Research, bringing its total funding to date to an impressive $85 million. The financing was anchored by Singular, with additional contributions from high-profile investors such as S32, redalpine, and influential figures like André Hoffmann, Vice-Chairman of Roche, Feike Sijbesma, Chair of Royal Philips, and Paul Polman, the former CEO of Unilever. The company plans to use the funds to accelerate its data collection efforts, enhancing its foundational dataset, which already outstrips conventional public databases utilized in the pharmaceutical research sector. By investing in cutting-edge AI capabilities and building on remarkable breakthroughs like outperforming AlphaFold-2, Basecamp Research aims to revolutionize the way biological problems are approached and solved, ultimately contributing to significant advancements in healthcare for patients worldwide.
They've invested in Basecamp Research
Get to know these Data investors
Click here for a full list of 6,908+ startup investors in the UK